Identification and Validation of Novel Biomarkers for Hepatocellular Carcinoma, Liver Fibrosis/Cirrhosis and Chronic Hepatitis B via Transcriptome Sequencing Technology

References

• Sun Z, Liu X, Wu D, et al. Circulating proteomic panels for diagnosis and risk stratification of acute-on-chronic liver failure in patients with viral hepatitis B. Theranostics. 2019;9(4):1200–1214. doi:10.7150/thno.31991
   PubMed Web of Science ®Google Scholar
• Wang X, Li MM, Niu Y, et al. Serum zonulin in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Dis Markers. 2019;2019:5945721. doi:10.1155/2019/5945721
   PubMed Web of Science ®Google Scholar
• Li L-J, Wu X-Y, Tan S-W, et al. Lnc-TCL6 is a potential biomarker for early diagnosis and grade in liver-cirrhosis patients. Gastroenterol Rep. 2019;7(6):434–443. doi:10.1093/gastro/goz050
   Google Scholar
• Xu H, Zhang S, Pan X, et al. TIMP-1 expression induced by IL-32 is mediated through activation of AP-1 signal pathway. Int Immunopharmacol. 2016;38:233–237. doi:10.1016/j.intimp.2016.06.002
   PubMed Web of Science ®Google Scholar
• Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68(12):2195–2205. doi:10.1136/gutjnl-2019-318882
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Su TH, et al. Fibrosis-4 index helps identify HBV carriers with the lowest risk of hepatocellular carcinoma. Am J Gastroenterol. 2017;112(10):1564–1574. doi:10.1038/ajg.2017.254
   PubMed Web of Science ®Google Scholar
• Ji D, Chen GF, Wang JC, et al. Identification of TAF1, HNF4A, and CALM2 as potential therapeutic target genes for liver fibrosis. J Cell Physiol. 2018;234(6):9045–9051. doi:10.1002/jcp.27579
   PubMed Web of Science ®Google Scholar
• Xie G, Wang X, Wei R, et al. Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection. BMC Med. 2020;18(1):144. doi:10.1186/s12916-020-01595-w
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Nakao H, Nishiyama T, et al. Diagnostic accuracy of real-time tissue elastography for the staging of liver fibrosis: a meta-analysis. Eur Radiol. 2015;25(1):230–238. doi:10.1007/s00330-014-3364-x
   PubMed Web of Science ®Google Scholar
• Kang YH, Park MY, Yoon DY, et al. Dysregulation of overexpressed IL-32 alpha in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-kappaB and Bcl-2. Cancer Lett. 2012;318(2):226–233. doi:10.1016/j.canlet.2011.12.023
   PubMed Web of Science ®Google Scholar
• Qian X, Liu S, Long H, et al. Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy. J Viral Hepat. 2020;28(1):20–29. doi:10.1111/jvh.13388
   PubMed Web of Science ®Google Scholar
• Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800–806. doi:10.1016/j.jhep.2015.11.035
   PubMed Web of Science ®Google Scholar
• Sharma SA, Kowgier M, Hansen BE, et al. Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol. 2017. doi:10.1016/j.jhep.2017.07.033
   Web of Science ®Google Scholar
• Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73(6):1368–1378. doi:10.1016/j.jhep.2020.07.025
   PubMed Web of Science ®Google Scholar
• Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16(11):1155–1161. doi:10.1038/nmat4997
   PubMed Web of Science ®Google Scholar
• Huang P, Feng X, Zhao Z, et al. p66Shc promotes HCC progression in the tumor microenvironment via STAT3 signaling. Exp Cell Res. 2019;383(2):111550. doi:10.1016/j.yexcr.2019.111550
   PubMed Web of Science ®Google Scholar
• Yoshida S, Masaki T, Feng H, et al. Enhanced expression of adaptor molecule p46 Shc in nuclei of hepatocellular carcinoma cells: study of LEC rats. Int J Oncol. 2004;25(4):1089–1096.
   PubMed Web of Science ®Google Scholar
• Ma H, Wang C, Liu X, Zhan M, Wei W, Niu J. Src homolog and collagen homolog1 isoforms in acute and chronic liver injuries. Life Sci. 2021;273:119302. doi:10.1016/j.lfs.2021.119302
   PubMed Web of Science ®Google Scholar
• Zhang R, Lin XH, Ma M, et al. Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition. J Transl Med. 2018;16(1):302. doi:10.1186/s12967-018-1676-3
   PubMed Web of Science ®Google Scholar
• Mir HA, Ali R, Mushtaq U, Khanday FA. Structure-functional implications of longevity protein p66Shc in health and disease. Ageing Res Rev. 2020;63:101139. doi:10.1016/j.arr.2020.101139
   PubMed Web of Science ®Google Scholar
• Li X, Kang C, Geng B, et al. PTRF/CAVIN1, regulated by SHC1 through the EGFR pathway, is found in urine exosomes as a potential biomarker of ccRCC. Carcinogenesis. 2020;41(3):274–283. doi:10.1093/carcin/bgz147
   PubMed Web of Science ®Google Scholar
• Qin W, Rong X, Yu C, Jia P, Yang J, Zhou G. Knockout of SLAMF8 attenuates collagen-induced rheumatoid arthritis in mice through inhibiting TLR4/NF-kappaB signaling pathway. Int Immunopharmacol. 2022;107:108644. doi:10.1016/j.intimp.2022.108644
   PubMed Web of Science ®Google Scholar
• Zou CY, Guan GF, Zhu C, et al. Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma. CNS Neurosci Ther. 2018;25(3):333–342. doi:10.1111/cns.13041
   PubMed Web of Science ®Google Scholar
• Zhang Q, Cheng L, Qin Y, et al. SLAMF8 expression predicts the efficacy of anti-PD1 immunotherapy in gastrointestinal cancers. Clin Transl Immunol. 2021;10(10):e1347. doi:10.1002/cti2.1347
   PubMed Web of Science ®Google Scholar
• Zeng X, Liu G, Peng W, et al. Combined deficiency of SLAMF8 and SLAMF9 prevents endotoxin-induced liver inflammation by downregulating TLR4 expression on macrophages. Cell Mol Immunol. 2020;17(2):153–162. doi:10.1038/s41423-018-0191-z
   PubMed Web of Science ®Google Scholar
• de Albuquerque R, Komsi E, Starskaia I, Ullah U, Lahesmaa R. The role of Interleukin-32 in autoimmunity. Scand J Immunol. 2021;93(2):e13012. doi:10.1111/sji.13012
   PubMed Web of Science ®Google Scholar
• Sloot YJE, Smit JW, Joosten LAB, Netea-Maier RT. Insights into the role of IL-32 in cancer. Semin Immunol. 2018;38:24–32. doi:10.1016/j.smim.2018.03.004
   PubMed Web of Science ®Google Scholar
• Kim DH, Park ES, Lee AR, et al. Intracellular interleukin-32 gamma mediates antiviral activity of cytokines against hepatitis B virus. Nat Commun. 2018;9(1):3284. doi:10.1038/s41467-018-05782-5
   PubMed Web of Science ®Google Scholar
• Zhao WB, Wang QL, Xu YT, Xu SF, Qiu Y, Zhu F. Overexpression of interleukin-32α promotes invasion by modulating VEGF in hepatocellular carcinoma. Oncol Rep. 2018;39(3):1155–1162. doi:10.3892/or.2017.6162
   PubMed Web of Science ®Google Scholar
• Wu D, Zhang S, Xie Z, et al. Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. J Clin Invest. 2020;130(4):2069–2080. doi:10.1172/JCI130197
   PubMed Web of Science ®Google Scholar
• Zhao G, Luo X, Han X, Liu Z. Combining bioinformatics and biological detection to identify novel biomarkers for diagnosis and prognosis of pulmonary tuberculosis. Saudi Med J. 2020;41(4):351–360. doi:10.15537/smj.2020.4.24989
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T; European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238–iv255. doi:10.1093/annonc/mdy308
   PubMed Web of Science ®Google Scholar
• Li D, Zhao D, Du J, et al. Heme oxygenase-1 alleviated non-alcoholic fatty liver disease via suppressing ROS-dependent endoplasmic reticulum stress. Life Sci. 2020;253:117678. doi:10.1016/j.lfs.2020.117678
   PubMed Web of Science ®Google Scholar
• Xu H, Zhang A, Han X, et al. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas. Cancer Immunol Immunother. 2022;71(3):645–660. doi:10.1007/s00262-021-03022-2
   PubMed Web of Science ®Google Scholar
• Sun Z, Dang Q, Liu Z, et al. LINC01272/miR-876/ITGB2 axis facilitates the metastasis of colorectal cancer via epithelial-mesenchymal transition. J Cancer. 2021;12(13):3909–3919. doi:10.7150/jca.55666
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang Y, Ling J, et al. Is integrin subunit alpha 2 expression a prognostic factor for liver carcinoma? A validation experiment based on bioinformatics analysis. Pathol Oncol Res. 2019;25(4):1545–1552. doi:10.1007/s12253-018-0551-0
   PubMed Web of Science ®Google Scholar
• He J, Li G, Liu X, et al. Diagnostic and prognostic values of MANF expression in hepatocellular carcinoma. Biomed Res Int. 2020;2020:1936385. doi:10.1155/2020/1936385
   PubMed Web of Science ®Google Scholar
• Liu J, Wu Z, Han D, et al. Mesencephalic astrocyte-derived neurotrophic factor inhibits liver cancer through Small Ubiquitin-Related Modifier (SUMO)ylation-related suppression of NF-kappaB/snail signaling pathway and epithelial-mesenchymal transition. Hepatology. 2020;71(4):1262–1278. doi:10.1002/hep.30917
   PubMed Web of Science ®Google Scholar
• Baselli GA, Dongiovanni P, Rametta R, et al. Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut. 2020;69(10):1855–1866. doi:10.1136/gutjnl-2019-319226
   PubMed Web of Science ®Google Scholar
• Qi F, Wang L, Huang P, Zhao Z, Yang B, Xia J. Time-series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma. Oncol Lett. 2020;19(2):1175–1186. doi:10.3892/ol.2019.11209
   PubMed Web of Science ®Google Scholar
• Liu H, Liu M, You H, Li X, Li X. Oncogenic network and hub genes for natural killer/T-cell lymphoma utilizing WGCNA. Front Oncol. 2020;10:223. doi:10.3389/fonc.2020.0022
   PubMed Web of Science ®Google Scholar
• Hendrickx DM, Jennen DG, Briedé JJ, Cavill R, de Kok TM, Kleinjans JC. Pattern recognition methods to relate time profiles of gene expression with phenotypic data: a comparative study. Bioinformatics. 2015;31(13):2115–2122. doi:10.1093/bioinformatics/btv108
   PubMed Web of Science ®Google Scholar
• Grossman SR, Lyle S, Resnick MB, et al. p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. Clin Cancer Res. 2007;13(19):5798–5804. doi:10.1158/1078-0432.CCR-07-0073
   PubMed Web of Science ®Google Scholar
• Pei JF, Li XK, Li WQ, et al. Diurnal oscillations of endogenous H2O2 sustained by p66(Shc) regulate circadian clocks. Nat Cell Biol. 2019;21(12):1553–1564. doi:10.1038/s41556-019-0420-4
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang Z, Zhou J, et al. LncRNA Mical2/miR-203a-3p sponge participates in epithelial-mesenchymal transition by targeting p66Shc in liver fibrosis. Toxicol Appl Pharmacol. 2020;403:115125. doi:10.1016/j.taap.2020.115125
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang Z, Feng D, et al. p66Shc contributes to liver fibrosis through the regulation of mitochondrial reactive oxygen species. Theranostics. 2019;9(5):1510–1522. doi:10.7150/thno.29620
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kornek M, Ikenaga N, et al. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013;58(5):1667–1680. doi:10.1002/hep.26526
   PubMed Web of Science ®Google Scholar
• De Calisto J, Wang N, Wang G, Yigit B, Engel P, Terhorst C. SAP-dependent and -independent regulation of innate T cell development involving SLAMF receptors. Front Immunol. 2014;5:186. doi:10.3389/fimmu.2014.00186
   PubMed Web of Science ®Google Scholar
• Sugimoto A, Kataoka TR, Ito H, et al. SLAM family member 8 is expressed in and enhances the growth of anaplastic large cell lymphoma. Sci Rep. 2020;10(1):2505. doi:10.1038/s41598-020-59530-1
   PubMed Web of Science ®Google Scholar
• Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. Pharmacol Ther. 2017;174:127–137. doi:10.1016/j.pharmthera.2017.02.025
   PubMed Web of Science ®Google Scholar
• Tian ZJ, Shen Y, Li XR, Wei YN, Fan H, Ren QK. Increased interleukin-32, interleukin-1, and interferon-gamma levels in serum from hepatitis B patients and in HBV-stimulated peripheral blood mononuclear cells from healthy volunteers. J Infect Public Health. 2019;12(1):7–12. doi:10.1016/j.jiph.2018.06.006
   PubMed Web of Science ®Google Scholar
• Zhu HT, Liu RB, Liang YY, et al. Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. Liver Int. 2017;37(6):888–896. doi:10.1111/liv.13356
   PubMed Web of Science ®Google Scholar
• Gao S, Xu X, Wang Y, Zhang W, Wang X. Diagnostic utility of plasma lncRNA small nucleolar RNA host gene 1 in patients with hepatocellular carcinoma. Mol Med Rep. 2018;18(3):3305–3313. doi:10.3892/mmr.2018.9336
   PubMed Web of Science ®Google Scholar
• Wu D, Zhang P, Ma J, et al. Serum biomarker panels for the diagnosis of gastric cancer. Cancer Med. 2019;8(4):1576–1583. doi:10.1002/cam4.2055
   PubMed Web of Science ®Google Scholar